成人骨髓增生异常综合征的管理策略
本文综述成人MDS的管理。预后仍主要基于IPSS和IPSS-R,分为较低危和较高危。较低危以改善血细胞减少(尤其贫血)为目标,较高危以延缓疾病进展和延长生存为目标,并分别讨论了去甲基化药物、来那度胺、异基因造血干细胞移植等治疗选择。
要点
- 较低危MDS无del(5q)者贫血一线用促红细胞生成素,二线药物多未获批。
- 较低危MDS伴del(5q)者来那度胺疗效显著。
- 较高危MDS中allo-SCT是唯一可能治愈手段,但适用者少。
核心结论
- MDS预后仍主要基于IPSS和IPSS-R分为较低危与较高危,治疗目标不同。
- 较低危以改善血细胞减少为主,较高危以延缓进展和延长生存为主。
- allo-SCT是较高危MDS唯一可能治愈手段,但很少适用。
研究设计与样本
- 本文为综述,讨论成人MDS的管理策略。
主要发现
- 较低危MDS无del(5q)者贫血一般先用促红细胞生成素,二线药物目前未获批或很少适用。
- 来那度胺在较低危MDS伴del(5q)者有主要疗效。
- 较高危MDS中allo-SCT前,骨髓原始细胞增多(尤其>10%)者一般先接受强化化疗或HMA。
- 其他较高危患者中HMA可改善生存。
- 新药如venetoclax及特定突变时的IDH1或IDH2抑制剂正在研究中。
关键数值与推荐
- 预后评分采用IPSS和修订IPSS。
- 骨髓原始细胞尤其>10%者allo-SCT前接受强化化疗或HMA。
- 强化化疗主要作为allo-SCT桥接,且无不良核型时使用。
- 较低危MDS多次红细胞输注时可考虑铁螯合。
临床怎么用
- 较低危MDS无del(5q)者贫血首先用促红细胞生成素。
- 较低危MDS伴del(5q)者用来那度胺。
- 较高危MDS骨髓原始细胞>10%者移植前用强化化疗或HMA。
- 特定突变者可考虑IDH1或IDH2抑制剂(研究中)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis in Myelodysplastic syndromes (MDS), although recently refined by molecular studies, remains largely based on conventional prognostic scores [International Prognostic Scoring System (IPSS), revised IPSS], classifying patients into "lower risk" MDS (LR-MDS) and "higher risk" MDS (HR-MDS). In LR-MDS, treatment mainly aims at improving cytopenias, principally anaemia, while in HR-MDS it aims at delaying disease progression and prolonging survival. In LR-MDS without deletion 5q, anaemia is generally treated first by erythropoietic stimulating factors, while second line treatments are currently not approved [lenalidomide, hypomethylating agents (HMA), luspatercept] or rarely indicated (antithymocyte globulin). Lenalidomide has major efficacy in LR-MDS with deletion 5q. Allogeneic stem cell transplantation (allo-SCT) is sometimes considered in LR-MDS, and iron chelation can be considered when multiple red blood cell transfusions are required. Allo-SCT is the only potentially curative treatment for HR-MDS; however, it is rarely applicable. It is generally preceded by intensive chemotherapy (IC) or HMA in patients with excess of marrow blasts (especially if >10%). In other patients, HMA can improve survival. The role of new drugs, including venetoclax or, in case of specific mutations, IDH1 or IDH2 inhibitors, is investigated. IC is mainly indicated as a bridge to allo-SCT, in the absence of unfavourable karyotype.
引用
- Fenaux P, Platzbecker U, Ades L, et al. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2019. PMID: 31568568. doi:10.1111/bjh.16206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。